Fax: (011) 49-6221-56-4920
Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma
An analysis of clinical presentation and outcome in 144 patients
Version of Record online: 26 JUN 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 1, pages 99–106, 1 January 2013
How to Cite
Heilgeist, A., McClanahan, F., Ho, A. D. and Witzens-Harig, M. (2013), Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma. Cancer, 119: 99–106. doi: 10.1002/cncr.27704
- Issue online: 17 DEC 2012
- Version of Record online: 26 JUN 2012
- Manuscript Accepted: 11 MAY 2012
- Manuscript Revised: 4 MAY 2012
- Manuscript Received: 22 MAR 2012
- marginal zone lymphoma;
- mucosa-associated lymphoid tissue;
- mucosa associated lymphoid tissue;
- Follicular Lymphoma International Prognostic Index;
In marginal zone lymphoma (MZL), clinical and follow-up data on large cohorts of patients are difficult to obtain. The objective of this single-center, retrospective analysis of a large cohort of 144 patients with MZL was to elucidate the role of prognostic markers, treatments, and outcomes in this disease.
In total, 144 patients were identified who were diagnosed with MZL at the authors' institution between 2003 and 2010. Data on clinical parameters, treatments, response, and survival were analyzed. In addition, the validity of the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) prognostic scores were tested in patients with MZL.
Among 144 patients with MZL, 96 patients (67%) had extralymph node (extranodal) MZL, 32 patients (22%) had lymph node (nodal) MZL, and 16 patients (11%) had splenic MZL. The 5-year progression-free survival rate was 82% in the nodal MZL group, 88% in the extranodal MZL group, and 74% in the splenic MZL group and did not different between the 3 groups (P = .60). The 5-year overall survival rate was excellent in all 3 MZL groups (nodal MZL, 89%; extranodal MZL, 92%; splenic MZL, 82%; P = .46). In our cohort, the FLIPI score was a significant prognostic marker: The 5-year progression-free survival rate for patients who had FLIPI scores of 0 to 2 (low or intermediate risk) was excellent at 92%, whereas it was only 62% for patients who had FLIPI scores of 3 to 5 (poor risk; P = .003). Similarly, the 5-year overall survival rate for patients who had FLIPI scores of 0 to 2 was 95%, whereas it was only 62% for patients who had FLIPI scores of 3 to 5 (P = .0009).
The FLIPI score had strong prognostic value in patients with MZL. Patients who have low-risk or intermediate-risk FLIPI scores have an excellent prognosis, whereas patients with poor-risk FLIPI scores are candidates for novel treatment approaches. Cancer 2013. © 2012 American Cancer Society.